SynthesisWorld journal of surgical oncology2025
Cytoreductive surgery with multimodal therapies in advanced or metastatic ovarian, colorectal, and gastric cancers: a systematic review and meta-analysis of randomized trials.
Synthesis in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundEmerging evidence supports cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian cancer, yet its efficacy in other malignancies, such as gastric and colorectal cancers, remains uncertain. This meta-analysis evaluates survival outcomes in patients with advanced or metastatic ovarian, colorectal, and gastric cancers treated with CRS and multimodal therapies (e.g., HIPEC, extensive intraoperative peritoneal lavage (EIPL), systemic chemotherapy, immunotherapy, targeted therapy) versus CRS alone or with control-based regimens, focusing on the applicability of these treatments to these specific cancers.
methodsWe systematically searched PubMed, EMBASE, Web of Science, the Cochrane Library, and the abstracts of the European Society of Medical Oncology (ESMO) and American Society of Clinical Oncology (ASCO) congresses up to April 21, 2025, for randomized trials published in English. The primary outcomes were overall survival (OS) and progression-free survival (PFS); secondary outcomes included mortality, adverse events, and 3- and 5-year OS rates. Hazard ratios (HRs) and 95% confidence intervals (CIs) were pooled using fixed- or random-effects models, depending on heterogeneity (I²).
findingsFrom 16,064 records, 13 studies (n = 3,925 patients, control group = 1,894, experimental group = 2,031) met inclusion criteria. The experimental group significantly improved OS (HR: 0.86, 95% CI: 0.77 - 0.95, P = 0.003, I² = 22%, P = 0.26) and PFS (HR: 0.67, 95% CI: 0.50 - 0.90, P = 0.009, I² = 83%, P < 0.001) compared to the control group. Subgroup analyses highlighted heterogeneity in PFS benefits, with recent trials (published in or after 2023) showing more potent effects (HR: 0.53, 95% CI: 0.44 - 0.64, P < 0.001). Mortality reduction favored the experimental group (risk ratio (RR): 0.86, 95% CI: 0.75 - 0.99, P = 0.03, I² = 26%, P = 0.24), though clinical relevance requires cautious interpretation. The experimental group significantly increased grade 3 or worse adverse events (RR: 1.31, 95% CI: 1.16 - 1.48, P < 0.001, I² = 31%, P = 0.04), with significant effects driven by digestive system (RR: 1.43, 95% CI: 1.06 - 1.93) and circulatory system (RR: 1.58, 95% CI: 1.07 - 2.32) events.
interpretationCRS combined with multimodal therapies, confers significant survival benefits in advanced ovarian, colorectal, and gastric cancers despite elevated complication risks. These findings support the tailored integration of multimodal strategies in selected patients, highlighting the need for robust randomized trials to validate long-term efficacy and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.